SCHEMBL7848606

SCHEMBL7848606

Oc1c(/N=N/c2ccc3cccc(O)c3n2)ccc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.59
▸ L3MBTL1 Q9Y468 4/20 0.59
▸ KDM4E B2RXH2 4/20 0.59
▸ MAPT P10636 3/20 0.59
▸ LMNA P02545 2/20 0.59
▸ OPRK1 P41145 2/20 0.59
▸ HTT P42858 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ PKM P14618 1/20 0.59
▸ NPC1 O15118 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ CTRB1 P17538 1/20 0.50
▸ PABPC1 P11940 1/20 0.50
▸ IDO1 P14902 1/20 0.50
▸ TDO2 P48775 1/20 0.50
▸ MPL P40238 1/20 0.48
▸ CTRC Q99895 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL387565 0.79 KMT2A (0.73) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL6550515 0.78 KMT2A (0.63) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL6550519 0.78 KMT2A (0.63) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL8660991 0.77 KMT2A (0.61) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL8971639 0.76 L3MBTL1 (0.65) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL8971645 0.76 L3MBTL1 (0.65) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL10781209 0.75 L3MBTL1 (0.63) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL284105 0.75 L3MBTL1 (1.00) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL31621738 0.75 L3MBTL1 (1.00) KMT2AL3MBTL1KDM4EMAPTLMNA
SCHEMBL284106 0.75 L3MBTL1 (1.00) KMT2AL3MBTL1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608066-B1 Treating mammal susceptible to, suffering from, suspected of having or recovering from disease impacted by tissue factor, such as cardiovascular, blood coagulation, cell proliferation or immune disorders, atherosclerosis, inflammation or cancer SUNOL MOLECULAR CORPORATION 2003-08-19 — — US disclosed
US-6608066-B1 Treating mammal susceptible to, suffering from, suspected of having or recovering from disease impacted by tissue factor, such as cardiovascular, blood coagulation, cell proliferation or immune disorders, atherosclerosis, inflammation or cancer SUNOL MOLECULAR CORPORATION 2003-08-19 — — US disclosed
Send feedback